We are live on
!
Find out more
BG
Bahl & Gaynor Portfolio holdings
AUM
$19.8B
1-Year Est. Return
19.53%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+19.53%
3 Year Est. Return
+63.97%
5 Year Est. Return
+84.2%
10 Year Est. Return
+296.44%
AUM
$18.6B
AUM Growth
+$2.56B
(+16%)
Cap. Flow
+$2.56B
Cap. Flow
% of AUM
13.76%
Top 10 Holdings %
Top 10 Hldgs %
30.44%
Holding
344
New
5
Increased
153
Reduced
150
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travelers Companies
TRV
|
+$126M |
| 2 |
Prologis
PLD
|
+$111M |
| 3 |
AbbVie
ABBV
|
+$110M |
| 4 |
Lockheed Martin
LMT
|
+$105M |
| 5 |
RTX Corp
RTX
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blackrock
BLK
|
+$129M |
| 2 |
American Tower
AMT
|
+$86.7M |
| 3 |
Fidelity National Information Services
FIS
|
+$85.5M |
| 4 |
Medtronic
MDT
|
+$50M |
| 5 |
Best Buy
BBY
|
+$49.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.01% |
| 2 | Healthcare | 14.45% |
| 3 | Financials | 12.75% |
| 4 | Consumer Staples | 12.05% |
| 5 | Industrials | 11.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SNV
326
DELISTED
Synovus
SNV
| $212K | ﹤0.01% |
6,874
| – | – |
|
327
Black Stone Minerals
BSM
$3B
| $212K | ﹤0.01% |
+13,500
| New | +$211K |
|
328
Yum! Brands
YUM
$41.1B
| $212K | ﹤0.01% |
1,602
-38
| -2% | -$4.89K |
|
329
Elevance Health
ELV
$85.5B
| $207K | ﹤0.01% |
450
+8
| +2% | +$3.81K |
|
330
Concentrix
CNXC
$1.57B
| $203K | ﹤0.01% |
1,672
| – | – |
|
331
Kimbell Royalty Partners
KRP
$1.48B
| $190K | ﹤0.01% |
12,500
| – | – |
|
|
EFC
332
Ellington Financial
EFC
$1.71B
| $153K | ﹤0.01% |
12,500
| – | – |
|
333
Plug Power
PLUG
$3.04B
| $124K | ﹤0.01% |
10,573
| – | – |
|
334
Nokia
NOK
$52.3B
| $108K | ﹤0.01% |
21,900
| – | – |
|
335
Onconetix
ONCO
$3.29M
| – | – |
0
| – | – |
|
336
CoStar Group
CSGP
$12.3B
| – | – |
-3,060
| Closed | -$236K |
|
337
Dollar General
DG
$27.9B
| – | – |
-946
| Closed | -$233K |
|
338
DexCom
DXCM
$32B
| – | – |
-1,853
| Closed | -$210K |
|
339
RB Global
RBA
$17.5B
| – | – |
-37,443
| Closed | -$2.17M |
|
340
Sarepta Therapeutics
SRPT
$1.77B
| – | – |
-1,597
| Closed | -$207K |
|
341
Verisk Analytics
VRSK
$25B
| – | – |
-1,407
| Closed | -$248K |
|
Similar funds
NIM
HHII
SPIA
MIM
EIM
OSAM
P
Bahl & Gaynor's Q1 2023 Portfolio in Review
As of Q1 2023, Bahl & Gaynor held 344 positions worth $18.6B, up 16% from $16B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Bahl & Gaynor deployed $2.56B of net new capital in Q1 2023, opening 5 new positions and adding to 153 existing holdings. Its largest new stake was Hartford Financial Services: 711,253 shares worth $49.6M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Blackrock, an estimated $129M trimmed.
- Bahl & Gaynor's largest Q1 2023 buy was Hartford Financial Services: 711,253 shares worth $49.6M.
- Bahl & Gaynor added most to Travelers Companies in Q1 2023, an estimated $126M increase.
- Bahl & Gaynor's biggest Q1 2023 reduction was Blackrock, cutting an estimated $129M.
- Bahl & Gaynor fully exited RB Global in Q1 2023, selling an estimated $2.17M.
- Bahl & Gaynor's ten largest holdings make up 30% of its $18.6B portfolio in Q1 2023.
- Bahl & Gaynor opened 5 new positions and closed 6 in Q1 2023.
- Bahl & Gaynor's portfolio value rose 16% quarter-over-quarter to $18.6B.
Based on Bahl & Gaynor's 13F filing for Q1 2023, filed 3 May 2023.